PMID- 30728910
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200225
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 10
IP  - 5
DP  - 2019 Jan 15
TI  - Improved survival outcomes and relative youthfulness of multiple myeloma patients 
      with t(4;14) receiving novel agents are associated with poorer performance of the 
      revised international staging system in a real aging society.
PG  - 595-605
LID - 10.18632/oncotarget.26562 [doi]
AB  - The Revised International Staging System (R-ISS) was developed for a more 
      accurate risk stratification of patients with symptomatic multiple myeloma (MM). 
      However, original and subsequent validation studies of the R-ISS included 
      relatively younger patients, many of whom were treated without bortezomib. Hence, 
      we investigated the real-world prognostic performance of the R-ISS in 400 
      patients with MM treated with novel agents in Japan, an aging society. The 
      patients had a median age of 72 years, and 96.0% were treated with bortezomib. 
      Patients in R-ISS stage II were significantly older and failed to show 
      significantly longer overall survival (OS) compared to patients in R-ISS stages 
      III (median age; 74 and 70 years, respectively; P = 0.001, and median OS; 63.4 
      vs. 54.7 months, respectively; P = 0.32). However, OS differed significantly 
      among patients with all conventional ISS stages. ISS stage III patients 
      recategorized to R-ISS stage III were significantly younger than those 
      recategorized to R-ISS stage II and had a relatively longer OS. As a reason for 
      these findings, patients with the high-risk cytogenetic abnormality t(4;14) were 
      significantly younger and had an improved OS compared to others, which can be 
      attributed to a young age and bortezomib therapy, as previously suggested. In 
      conclusion, the R-ISS was less successful than the ISS in discriminating between 
      stages II and III among bortezomib-treated patients with MM in an aging society, 
      which might be attributable to the inclusion of t(4;14) in the R-ISS 
      categorization strategy.
FAU - Abe, Yoshiaki
AU  - Abe Y
AD  - Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical 
      Center, Chiba, Japan.
FAU - Sunami, Kazutaka
AU  - Sunami K
AD  - Department of Hematology, National Hospital Organization Okayama Medical Center, 
      Okayama, Japan.
FAU - Yamashita, Takeshi
AU  - Yamashita T
AD  - Department of Internal Medicine, Keiju Kanazawa Hospital, Ishikawa, Japan.
FAU - Ueda, Mikio
AU  - Ueda M
AD  - Department of Internal Medicine, Keiju Kanazawa Hospital, Ishikawa, Japan.
FAU - Takamatsu, Hiroyuki
AU  - Takamatsu H
AD  - Department of Hematology/Respiratory Medicine, Faculty of Medicine, Institute of 
      Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, 
      Japan.
FAU - Narita, Kentaro
AU  - Narita K
AD  - Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical 
      Center, Chiba, Japan.
FAU - Kobayashi, Hiroki
AU  - Kobayashi H
AD  - Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical 
      Center, Chiba, Japan.
FAU - Kitadate, Akihiro
AU  - Kitadate A
AD  - Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical 
      Center, Chiba, Japan.
FAU - Takeuchi, Masami
AU  - Takeuchi M
AD  - Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical 
      Center, Chiba, Japan.
FAU - Matsue, Kosei
AU  - Matsue K
AD  - Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical 
      Center, Chiba, Japan.
LA  - eng
PT  - Journal Article
DEP - 20190115
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC6355174
OTO - NOTNLM
OT  - aging
OT  - multiple myeloma
OT  - prognosis
OT  - revised international staging system
OT  - t(4;14)
COIS- CONFLICTS OF INTEREST The authors have no conflicts of interest.
EDAT- 2019/02/08 06:00
MHDA- 2019/02/08 06:01
PMCR- 2019/01/15
CRDT- 2019/02/08 06:00
PHST- 2018/10/06 00:00 [received]
PHST- 2018/12/27 00:00 [accepted]
PHST- 2019/02/08 06:00 [entrez]
PHST- 2019/02/08 06:00 [pubmed]
PHST- 2019/02/08 06:01 [medline]
PHST- 2019/01/15 00:00 [pmc-release]
AID - 26562 [pii]
AID - 10.18632/oncotarget.26562 [doi]
PST - epublish
SO  - Oncotarget. 2019 Jan 15;10(5):595-605. doi: 10.18632/oncotarget.26562. 
      eCollection 2019 Jan 15.